Real-World Prescribing Patterns and Treatment Continuation of Amitriptyline Monotherapy and Aripiprazole Augmentation for Medically Unexplained Oral Symptoms/Syndromes in Japan.

Observations from the aripiprazole combination group showed a trend towards a relatively lower treatment discontinuation hazard in the dosage range of 1.7–1.8 mg/day, but this is merely an observed association, suggesting that escalation beyond this dosage may not necessarily contribute to treatment continuation.

also in 53,322 other papers